特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

難治性狭心症:2030年までの市場分析、疫学、市場予測

Refractory Angina - Market Insights, Epidemiology and Market Forecast - 2030

発行 DelveInsight Business Research LLP 商品コード 934327
出版日 ページ情報 英文 131 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.57円で換算しております。
難治性狭心症:2030年までの市場分析、疫学、市場予測 Refractory Angina - Market Insights, Epidemiology and Market Forecast - 2030
出版日: 2020年05月01日 ページ情報: 英文 131 Pages
担当者のコメント
難治性狭心症の主要7か国における2030年度までの市場予測をはじめ、疫学データ、新たな治療手法、治療ガイドライン、ケーススタディなど、詳細をまとめたレポートがDelve Insightよりリリースされました。まずはサンプルページをお送りさせていただきますので、お問い合わせください。
概要

当レポートは、世界の難治性狭心症関連市場を調査したもので、市場の概要、 疫学と患者数、国別の状況、治療法、ケーススタディ、関連組織、主な地域市場の分 析などの情報を提供しています。

目次

第1章 主な調査結果

第2章 難治性狭心症の概要

第3章 難治性狭心症関連市場のSWOT分析

第4章 難治性狭心症(RA)関連市場の概要

  • 2017年の市場シェア
  • 2030年の市場シェア

第5章 疾患の背景と概要

  • イントロダクション
  • タイプ
  • 症状
  • 病因
  • 危険因子
  • 病態生理学
  • 診断

第6章 疫学と患者数

  • 主な調査結果
  • 患者数の合計

第7章 疫学的な前提条件と根拠

第8章 各国の疫学的分析

  • 米国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
  • 日本

第9章 治療

  • 薬理療法
  • 非侵襲的な抗狭心症療法
  • 侵襲性抗狭心症療法
  • 治療ガイドライン
    • 難治性狭心症患者のための欧州心臓病学会(ESC)ガイドライン
    • National Institute for Health and Clinical Excellence(NICE)ガイドラ イン:最近発症した胸痛
    • カナダ心血管学会(CCS)ガイドライン

第10章 未対応のニーズ

第11章 ケーススタディ

  • 難治性狭心症の症例
  • 難治性狭心症の症例報告

第12章 難治性狭心症に関連する組織

第13章 新たな治療法

  • IMB-101: Umbria Pharmaceuticals
  • Auto CD34 + Cells:Calandrias Biosciences、Inc.
  • Generx:Antiemetics Inc.
  • XC001:XyloCor Therapeutics、Inc.

第14章 7つの主要な市場の分析

  • 主な調査結果
  • 市場規模
  • 市場の展望

第15章 米国

  • 市場規模
  • 治療法別の市場規模

第16章 欧州

  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国

第17章 日本

第18章 市場成長要因

第19章 市場の障壁

第20章 付録

  • 参考文献
  • レポート調査手法

第21章 サービス内容

第22章 免責事項

第23章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Refractory Angina (RA) Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Difference between Stable and Unstable Angina
  • Table 3: Probability of Coronary Artery Diseases and Associated Diagnostic Strategies
  • Table 4: Total Prevalent Patient Population of RA in 7MM (2017-2030)
  • Table 5: Diagnosed Population of CAD and RA in the United States (2017-2030)
  • Table 6: Sub-type Specific Prevalence of RA in the United States (2017-2030)
  • Table 7: Gender specific Prevalence of RA in the United States (2017-2030)
  • Table 8: Diagnosed Population of NORDA in the US (2017-2030)
  • Table 9: Total Prevalent Population of RA in Germany (2017-2030)
  • Table 10: Sub-type Specific Prevalence of RA in Germany (2017-2030)
  • Table 11: Gender specific Prevalence of RA in Germany (2017-2030)
  • Table 12: Diagnosed Population of NORDA in Germany (2017-2030)
  • Table 13: Diagnosed Population of CAD and RA in France (2017-2030)
  • Table 14: Sub-type Specific Prevalence of RA in France (2017-2030)
  • Table 15: Gender specific Prevalence of RA in France (2017-2030)
  • Table 16: Diagnosed Population of NORDA in France (2017-2030)
  • Table 17: Diagnosed Population of CAD and RA in Italy (2017-2030)
  • Table 18: Sub-type Specific Prevalence of RA in Italy (2017-2030)
  • Table 19: Gender specific Prevalence of RA in Italy (2017-2030)
  • Table 20: Diagnosed Population of NORDA in Italy (2017-2030)
  • Table 21: Diagnosed Population of CAD and RA in Spain (2017-2030)
  • Table 22: Sub-type Specific Prevalence of RA in Italy (2017-2030)
  • Table 23: Gender specific Prevalence of RA in Spain (2017-2030)
  • Table 24: Diagnosed Population of NORDA in Spain (2017-2030)
  • Table 25: Diagnosed Population of CAD and RA in the UK (2017-2030)
  • Table 26: Sub-type Specific Prevalence of RA in the UK (2017-2030)
  • Table 27: Gender specific Prevalence of RA in the United Kingdom (2017-2030)
  • Table 28: Diagnosed Population of NORDA in the UK (2017-2030)
  • Table 29: Diagnosed Population of CAD and RA in Japan (2017-2030)
  • Table 30: Sub-type Specific Prevalence of RA in Japan (2017-2030)
  • Table 31: Gender specific Prevalence of RA in Japan (2017-2030)
  • Table 32: Diagnosed Population of NORDA in Japan (2017-2030)
  • Table 33: Grading of Angina Pectoris
  • Table 34: Organizations contributing toward Refractory Angina
  • Table 35: IMB-101, Clinical Trial Description, 2020
  • Table 36: Auto CD34+ cells, Clinical Trial Description, 2020
  • Table 37: Generx, Clinical Trial Description, 2020
  • Table 38: XC001, Clinical Trial Description, 2020
  • Table 39: 7 Major Market Size of RA in USD Million (2017-2030)
  • Table 40: The US Market size of RA in USD Million (2017-2030)
  • Table 41: The US market size of RA by Therapies in USD Million (2017-2030)
  • Table 42: Germany Market size of RA in USD Million (2017-2030)
  • Table 43: Germany market size of RA by Therapies in USD Million (2017-2030)
  • Table 44: France Market size of RA in USD Million (2017-2030)
  • Table 45: France market size of RA by Therapies in USD Million (2017-2030)
  • Table 46: Italy Market size of RA in USD Million (2017-2030)
  • Table 47: Italy market size of RA by Therapies in USD Million (2017-2030)
  • Table 48: Spain Market size of RA in USD Million (2017-2030)
  • Table 49: Spain market size of RA by Therapies in USD Million (2017-2030)
  • Table 50: The UK Market size of RA in USD Million (2017-2030)
  • Table 51: The UK market size of RA by Therapies in USD Million (2017-2030)
  • Table 52: Japan Market size of RA in USD Million (2017-2030)
  • Table 53: Japan market size of RA by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Normal and Plaque Buildup Artery
  • Figure 3: Pictorial Representation of Different Types of Angina
  • Figure 4: Few of the causes of Chest Pain
  • Figure 5: Mechanisms and Pathways involved in Cardiac Chest Pain
  • Figure 6: The Heart-Brain Axis Model of Angina Physiopathology and Related Therapeutic Targets
  • Figure 7: Diagnosis of Chest Pain Symptoms according to Anginal Symptoms
  • Figure 8: Diagnostic Interventions
  • Figure 9: Definite Diagnosis
  • Figure 10: Total Prevalent Patient Population of RA in 7MM (2017-2030)
  • Figure 11: Diagnosed Population of CAD and RA in the United States (2017-2030)
  • Figure 12: Sub-type Specific Prevalence of RA in the United States (2017-2030)
  • Figure 13: Gender specific Prevalence of RA in the United States (2017-2030)
  • Figure 14: Diagnosed Population of NORDA in the US (2017-2030)
  • Figure 15: Diagnosed Population of CAD and RA in Germany (2017-2030)
  • Figure 16: Sub-type Specific Prevalence of RA in Germany (2017-2030)
  • Figure 17: Gender specific Prevalence of RA in Germany (2017-2030)
  • Figure 18: Diagnosed Population of NORDA in Germany (2017-2030)
  • Figure 19: Diagnosed Population of CAD and RA in France (2017-2030)
  • Figure 20: Sub-type Specific Prevalence of RA in France (2017-2030)
  • Figure 21: Gender specific Prevalence of RA in France (2017-2030)
  • Figure 22: Diagnosed Population of NORDA in France (2017-2030)
  • Figure 23: Diagnosed Population of CAD and RA in Italy (2017-2030)
  • Figure 24: Sub-type Specific Prevalence of RA in Italy (2017-2030)
  • Figure 25: Gender specific Prevalence of RA in Italy (2017-2030)
  • Figure 26: Diagnosed Population of NORDA in Italy (2017-2030)
  • Figure 27: Diagnosed Population of CAD and RA in Spain (2017-2030)
  • Figure 28: Sub-type Specific Prevalence of RA in Spain (2017-2030)
  • Figure 29: Gender specific Prevalence of RA in Spain (2017-2030)
  • Figure 30: Diagnosed Population of NORDA in Spain (2017-2030)
  • Figure 31: Diagnosed Population of CAD and RA in the UK (2017-2030)
  • Figure 32: Sub-type Specific Prevalence of RA in the UK (2017-2030)
  • Figure 33: Gender specific Prevalence of RA in the United Kingdom (2017-2030)
  • Figure 34: Diagnosed Population of NORDA in the UK (2017-2030)
  • Figure 35: Diagnosed Population of CAD and RA in Japan (2017-2030)
  • Figure 36: Sub-type Specific Prevalence of RA in Japan (2017-2030)
  • Figure 37: Gender specific Prevalence of RA in Japan (2017-2030)
  • Figure 38: Diagnosed Population of NORDA in Japan (2017-2030)
  • Figure 39: Treatments Addressing Myocardial Perfusion
  • Figure 40: Treatments Addressing Neural Processing
  • Figure 41: Treatment Landscape of Refractory Angina
  • Figure 42: Possible Combinations of Anti-anginal Drugs
  • Figure 43: Technique of enhanced external counterpulsation
  • Figure 44: Possible mechanisms responsible for the clinical benefit associated with EECP therapy
  • Figure 45: Pictorial Representation of Neuromodulation Targets
  • Figure 46: Pictorial Representation of Coronary Sinus Reducer
  • Figure 47: Clinical Assessment of Angina
  • Figure 48: Clinical assessment and the typicality of anginal pain
  • Figure 49: Unmet Needs of RA
  • Figure 50: 7 Major Market Size of RA in USD Million (2017-2030)
  • Figure 51: Market Size of RA in the United States, USD Millions (2017-2030)
  • Figure 52: The U.S. market size of RA by therapies in USD Million (2017-2030)
  • Figure 53: Market Size of RA in Germany, USD Millions (2017-2030)
  • Figure 54: Germany market size of RA by therapies in USD Million (2017-2030)
  • Figure 55: Market Size of RA in France, USD Millions (2017-2030)
  • Figure 56: France market size of RA by therapies in USD Million (2017-2030)
  • Figure 57: Market Size of RA in Italy, USD Millions (2017-2030)
  • Figure 58: Italy market size of RA by therapies in USD Million (2017-2030)
  • Figure 59: Market Size of RA in Spain, USD Millions (2017-2030)
  • Figure 60: Spain market size of RA by therapies in USD Million (2017-2030)
  • Figure 61: Market Size of RA in the UK, USD Millions (2017-2030)
  • Figure 62: The UK market size of RA by therapies in USD Million (2017-2030)
  • Figure 63: Market Size of RA in Japan, USD Millions (2017-2030)
  • Figure 64: Japan market size of RA by therapies in USD Million (2017-2030)
  • Figure 65: Market Drivers
  • Figure 66: Market Barriers
目次
Product Code: DIMI0606

DelveInsight's 'Refractory Angina (RA) - Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of RA in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Refractory Angina (RA) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Refractory Angina (RA) - Disease Understanding and Treatment Algorithm

Refractory Angina (RA) is a chronic condition where pain remain persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart. Angina has two types, chronic or stable angina and unstable angina. Around 10-15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease (CAD).

The goal of medicine is to improve the patient's quantity and quality of life. In the case of coronary artery disease, disease-modifying treatments have proved to be beneficial. The mainstay of anginal pain treatment is still based on nitrates, beta-blockers, calcium antagonists (with the addition of ranolazine and ivabradine), and coronary revascularization. These treatments match myocardial O2 supply and demand through variable mechanisms: coronary flow reserve increase, heart rate reduction, myocardial inotropy modulation, and improvements in cellular metabolism. Despite the optimal combination of such therapeutics, a substantial proportion of stable CAD patients continues to experience disabling angina resulting in the impairment in quality of life of the patients constituting refractory angina pectoris (RAP) population.

The DelveInsight Refractory Angina (RA) market report gives the thorough understanding of the Refractory Angina by including details such as disease definition, classification, symptoms, etiology, pathophysiology, complications, biomarkers and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Refractory Angina in the US, Europe and Japan.

Refractory Angina Epidemiology

The Refractory Angina (RA) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Population of Coronary Artery Disease and Refractory Angina, Sub-type Specific Prevalence, Gender-specific Prevalent Population of Refractory Angina and Diagnosed Population of NORDA) scenario of Refractory Angina (RA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

According to DelveInsight, the total number of prevalent cases of Refractory Angina (RA) in 7 MM was found to be 29,17,196 in the year 2017.

Refractory Angina Drug Chapters

This segment of the Refractory Angina report encloses the detailed analysis of marketed drugs and early stage (Phase-I and Phase-II) pipeline drugs along with other promising candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

A multidisciplinary treatment approach is usually followed internationally for the management of RA and the market consequently can be divided into segments based on revenue generated by therapies which include pain control, management of exocrine and endocrine insufficiency and management of other complications. However, there are important points to be noted such as the fact that there are not curative treatment options at present and all the therapies used are either off-label or symptomatic in nature.

Refractory Angina Market Outlook

The Refractory Angina market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Refractory Angina in 7MM was found to be USD 1387 Million in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of RA, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Refractory Angina Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Refractory Angina Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Refractory Angina Report Key Strengths

  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Refractory Angina Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Refractory Angina market
  • Organize sales and marketing efforts by identifying the best opportunities for Refractory Angina market
  • To understand the future market competition in the Refractory Angina market.

Table of Contents

1. Key Insights

2. Executive Summary of Refractory Angina

3. SWOT Analysis for Refractory Angina

4. Refractory Angina (RA) Market Overview at a Glance

  • 4.1. Market Share (%) Distribution of Refractory Angina (RA) in 2017
  • 4.2. Market Share (%) Distribution of Refractory Angina (RA) in 2030

5. Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Types
  • 5.3. Symptoms
  • 5.4. Etiology
  • 5.5. Risk Factors
  • 5.6. Pathophysiology
  • 5.7. Diagnosis

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Prevalent Patient Population of Refractory Angina [RA]

7. Epidemiology Assumptions and Rationale - 7MM

8. Country Wise-Epidemiology of Refractory Angina (RA)

  • 8.1. The United States
    • 8.1.1. Total Diagnosed Population of CAD and RA in the United States
    • 8.1.2. Sub-type Specific Prevalence of RA in the United States
    • 8.1.3. Gender specific Prevalence of RA in the United States
    • 8.1.4. Diagnosed Population of NORDA in the US
  • 8.2. Germany
    • 8.2.1. Total Diagnosed Population of CAD and RA in Germany
    • 8.2.2. Sub-type Specific Prevalence of RA in Germany
    • 8.2.3. Gender specific Prevalence of RA in Germany
    • 8.2.4. Diagnosed Population of NORDA in Germany
  • 8.3. France
    • 8.3.1. Total Diagnosed Population of CAD and RA in France
    • 8.3.2. Sub-type Specific Prevalence of RA in France
    • 8.3.3. Gender specific Prevalence of RA in France
    • 8.3.4. Diagnosed Population of NORDA in France
  • 8.4. Italy
    • 8.4.1. Total Diagnosed Population of CAD and RA in Italy
    • 8.4.2. Sub-type Specific Prevalence of RA in Italy
    • 8.4.3. Gender specific Prevalence of RA in Italy
    • 8.4.4. Diagnosed Population of NORDA in Italy
  • 8.5. Spain
    • 8.5.1. Total Diagnosed Population of CAD and RA in Spain
    • 8.5.2. Sub-type Specific Prevalence of RA in Spain
    • 8.5.3. Gender specific Prevalence of RA in Spain
    • 8.5.4. Diagnosed Population of NORDA in Spain
  • 8.6. The United Kingdom
    • 8.6.1. Total Diagnosed Population of CAD and RA in the UK
    • 8.6.2. Sub-type Specific Prevalence of RA in the UK
    • 8.6.3. Gender specific Prevalence of RA in the United Kingdom
    • 8.6.4. Diagnosed Population of NORDA in the United Kingdom
  • 8.7. Japan
    • 8.7.1. Total Diagnosed Population of CAD and RA in Japan
    • 8.7.2. Sub-type Specific Prevalence of RA in Japan
    • 8.7.3. Gender specific Prevalence of RA in Japan
    • 8.7.4. Diagnosed Population of NORDA in Japan

9. Treatment

  • 9.1. Pharmacological Therapies
  • 9.2. Noninvasive Antianginal therapies
  • 9.3. Invasive Antianginal therapies
  • 9.4. Treatment Guidelines
    • 9.4.1. European Society of Cardiology (ESC) Guidelines for Refractory Angina Patients
    • 9.4.2. National Institute for Health and Clinical Excellence (NICE) guidelines: Chest pain of recent onset
    • 9.4.3. Canadian Cardiovascular Society (CCS) Guidelines

10. Unmet Needs

11. Case Studies

  • 11.1. A Case of Refractory Angina
  • 11.2. A Case Report of Refractory Angina

12. Organizations related with Refractory Angina

13. Emerging Therapies

  • 13.1. IMB-101: Umbria Pharmaceuticals
    • 13.1.1. Other Developmental Activities
    • 13.1.2. Clinical Development
    • 13.1.3. Safety and Efficacy
  • 13.2. Auto CD34+ Cells: Calandrias Biosciences, Inc.
    • 13.2.1. Other Developmental Activities
    • 13.2.2. Clinical Development
    • 13.2.3. Safety and Efficacy
  • 13.3. Generx: Antiemetics Inc.
    • 13.3.1. Other Developmental Activities
    • 13.3.2. Clinical Development
    • 13.3.3. Safety and Efficacy
  • 13.4. XC001: XyloCor Therapeutics, Inc.
    • 13.4.1. Other Developmental Activities
    • 13.4.2. Clinical Development

14. Refractory Angina (RA): 7 Major Market Analysis

  • 14.1. Key Findings
  • 14.2. Total Market Size of RA in 7MM
  • 14.3. Market Outlook: 7MM

15. United States

  • 15.1. Total Market size of RA
  • 15.2. RA Market Size by Therapies

16. EU5 Countries

  • 16.1. Germany
    • 16.1.1. Total Market size of RA
    • 16.1.2. RA Market Size by Therapies
  • 16.2. France
    • 16.2.1. Total Market size of RA
    • 16.2.2. RA Market Size by Therapies
  • 16.3. Italy
    • 16.3.1. Total Market size of RA
    • 16.3.2. RA Market Size by Therapies
  • 16.4. Spain
    • 16.4.1. Total Market size of RA
    • 16.4.2. RA Market Size by Therapies
  • 16.5. United Kingdom
    • 16.5.1. Total Market size of RA
    • 16.5.2. RA Market Size by Therapies

17. Japan

  • 17.1. Total Market size of RA
  • 17.2. RA Market Size by Therapies

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight